erlotinib hydrochloride has been researched along with Precancerous Conditions in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beitler, JJ; Chen, AY; Chen, Z; Chen, ZG; El-Deiry, MW; Khuri, FR; Klein, AM; Liu, Y; Nannapaneni, S; Owonikoko, TK; Patel, MR; Ramalingam, SS; Roser, SM; Saba, NF; Shi, Q; Shin, DM; Steuer, CE | 1 |
| Liu, J; Xie, A | 1 |
| Blair, EA; Boyle, JO; Cohen, EE; El-Naggar, A; Gillenwater, AM; Gutkind, JS; Heymach, JV; Kim, ES; Lee, JJ; Lin, HY; Lingen, MW; Lippman, SM; Mao, L; Martin, JW; Meiller, T; Myers, J; Papadimitrakopoulou, V; Saintigny, P; Shin, DM; Shinn, N; Tang, X; Vigneswaran, N; William, WN; Wistuba, II | 1 |
| Bauman, JE; Grandis, J | 1 |
| Printz, C | 1 |
1 review(s) available for erlotinib hydrochloride and Precancerous Conditions
| Article | Year |
|---|---|
Chemoprevention of oral cancer in leukoplakia patients: A systematic review and meta-analysis.
Topics: Antineoplastic Agents; beta Carotene; Chemoprevention; Erlotinib Hydrochloride; Humans; Isotretinoin; Leukoplakia, Oral; Mouth Neoplasms; Precancerous Conditions; Provitamins; Tea; Treatment Outcome; Vitamin A; Vitamins | 2017 |
2 trial(s) available for erlotinib hydrochloride and Precancerous Conditions
| Article | Year |
|---|---|
Phase Ib Study of Chemoprevention with Green Tea Polyphenon E and Erlotinib in Patients with Advanced Premalignant Lesions (APL) of the Head and Neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Catechin; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Precancerous Conditions; Progression-Free Survival; Protein Kinase Inhibitors; Tea | 2020 |
Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial.
Topics: Administration, Oral; Anticarcinogenic Agents; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Loss of Heterozygosity; Male; Middle Aged; Mouth Neoplasms; Precancerous Conditions; Prospective Studies; Protein Kinase Inhibitors; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; United States | 2016 |
2 other study(ies) available for erlotinib hydrochloride and Precancerous Conditions
| Article | Year |
|---|---|
Oral Cancer Chemoprevention--The End of EPOC, the Beginning of an Epoch of Molecular Selection.
Topics: Anticarcinogenic Agents; Erlotinib Hydrochloride; Female; Humans; Male; Mouth Neoplasms; Precancerous Conditions; Protein Kinase Inhibitors | 2016 |
Developments in precision medicine: Studies highlight new applications for cancer chemoprevention, treatment.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemoprevention; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Estrogen Receptor alpha; Female; Humans; Loss of Heterozygosity; Mouth Neoplasms; Precancerous Conditions; Precision Medicine | 2016 |